Upcoming Medical Policies
BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process.  The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 8/9/2014

Topics due to be included in the Medical Policy Manual on 8/19/2014

Topics due to be included in the Medical Policy Manual on 9/14/2014

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 8/9/2014:

Collagenase Clostridium Histolyticum

Gene Expression Profile Analysis for Prostate Cancer Management

Positron Emission Tomography (PET) for Miscellaneous Applications

Topics due to be included in the Medical Policy Manual on 8/19/2014:

Bariatric Surgery

Genetic Testing (CFTR Mutations) for Cystic Fibrosis

Romidepsin

Topics due to be included in the Medical Policy Manual on 9/14/2014:

Donor Lymphocyte Infusion for Hematologic Malignancies


Last Review Date: 7/17/2014